Etiopathogenesis, Classical Immunotherapy and Innovative Nanotherapeutics for Inflammatory Neurological Disorders

• Type: Article in International Scientific Journal
• Date: 2011

Authors

Sa, MJ (Author) Other; Joana Guimaraes (Author) FMUP; Pedro Abreu (Author) FMUP; Mendes, A (Author) Other; Souto, EB (Author) Other

Journal

Title: Current Nanoscience

Vol. 7

Pages: 2-20

ISSN: 1573-4137

Publisher: Bentham Science

Indexing

ISI Web of Knowledge - 3 Citations

Scopus - 6 Citations

Other information

Authenticus ID: P-002-VDA

DOI: 10.2174/157341311794480318

Abstract (EN): Central nervous system (CNS) inflammation and neurological diseases are clinical conditions requiring a multifaceted spectrum of immunotherapies. The present paper reviews the etiopathogeny of demyelinating diseases located in the CNS (e.g., multiple sclerosis, acute disseminated encephalomyelitis, and neuromyelitis optica), and in the peripheral nervous system (e.g., acute/chronic idio-phathic inflammatory polyradiculoneuritis, and other dysimmune neuropathies). The pharmacological treatments here discussed include non-specific strategies (e.g., glucocorticoids, intravenous immunoglobulin) and others more specific, such as human IFN beta, glatiramer acetate, mitoxantrone, monoclonal antibodies, fingolimod, laquinimod, cladribine, fumarate, teriflunomide. The immunotherapies are described in terms of their specific and/or multiple activity in the disease stage of development (i.e., initiation, central/peripheral activation, molecular stimulation and immune effector responses during early, transitional and late phases). In the light of the current pharmacological treatments, novel site specific approaches using nanoparticles are briefly addressed.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 19